This story has important implications for our work lowering the age of consent to buy and test the home HIV test kits – from 17 to 15. We are considering filing suit too.
FDA Lowers Age Restriction On Plan B Morning-After Pill
The Huffington Post reported in a story published May 30:
The Food and Drug Administration announced on Tuesday that it will make a brand of emergency contraception known as Plan B One-Step available over the counter for women ages 15 and older, and with a prescription for younger teens. The pill is currently available over the counter to women ages 17 and older.
“Research has shown that access to emergency contraceptive products has the potential to further decrease the rate of unintended pregnancies in the United States,” said FDA Commissioner Margaret Hamburg in a statement. “The data reviewed by the agency demonstrated that women 15 years of age and older were able to understand how Plan B One-Step works, how to use it properly, and that it does not prevent the transmission of a sexually transmitted disease.”
The decision by the FDA only partially complies with a ruling handed down by a federal judge in early April, which instructed the FDA to lift all age restrictions on Plan B and make it available to everyone on pharmacy shelves. A panel of scientists at the FDA had recommended in 2011 that age restrictions be lifted on the morning-after pill, but Secretary of Health and Human Services Kathleen Sebelius overruled that recommendation, arguing that there was a lack of evidence showing that those under the age of 17 would use the pill appropriately.
By dropping the age limit to 15 instead of removing the limit entirely, the FDA has ensured that all women will still have to show an ID to the cashier in order to purchase the emergency contraception.
Sen. Patty Murray (D-Wash.) called the FDA’s decision a “step in the right direction.”
“This decision is a step in the right direction for increased access to a product that is a safe and effective method of preventing unintended pregnancies,” Murray said in a statement. “It’s also a decision that moves us closer to these critical availability decisions being based on science, not politics. Plan B is an essential part of a woman’s basic health care and I will continue to push for more information from FDA and HHS on the practical application of this policy while also working to ensure that access is based on science, safety, and efficacy.”
The Center for Reproductive Rights, which filed the lawsuit against Sebelius and the FDA that led to the judge’s ruling in April, said on Tuesday that it is not satisfied with the FDA’s decision.